BMS, WuXi PharmaTech in Shanghai Stability Pact

Bristol-Myers Squibb and WuXi PharmaTech have entered a strategic partnership to conduct stability studies of small-molecule new chemical entities to support global marketing applications. WuXi will build and operate a dedicated, 25,000-sq.-ft. cGMP analytical testing facility in Shanghai to store and test stability samples and perform other services for BMS. WuXi will also employ a staff for stability testing, sample management, analytical testing, pharmaceutical science, quality assurance, metrology and other services, including stability data reporting to support BMS’ global dossier submissions.

“This new agreement expands our already productive relationship with BMS, a valued customer for many years,” said Ge Li, Ph.D., chairman and chief executive officer of WuXi PharmaTech. “We will continue to help them to improve their R&D productivity with our innovation-driven, cost-effective and fully integrated R&D service platform.”

“WuXi PharmaTech is an important partner for BMS’ R&D organization,” said Mark Powell, Ph.D., senior vice president, Non-Clinical Development, BMS. “This agreement will expand the scope of our relationship with WuXi and enhance the presence of BMS in China. It is also an example of our R&D organization executing our company’s BioPharma model by using selective integration to leverage the strengths and talents of both Bristol-Myers Squibb and a valued partner.”